We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

4 hedge funds and large institutions have $550K invested in Loncar China BioPharma ETF in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $451K → $550K (+$98.9K)

3.82% more ownership

Funds ownership: 9.95% → 13.77% (+3.8%)

0% more funds holding

Funds holding: 4 → 4 (0)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$113K
2
GS
GTS Securities
Florida
+$51K

Top Sellers

No sellers this quarter

CHNA Hedge Fund Activity: Q3 2023 in Review

4 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2023, worth a combined $550K — up 22% from $451K a quarter earlier.

Fund positioning in CHNA was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, adding an estimated $113K.

  • 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $550K of Loncar China BioPharma ETF stock for Q3 2023, up 22% quarter-over-quarter.
  • 0 funds opened new Loncar China BioPharma ETF positions in Q3 2023 and 0 closed out.
  • The largest Loncar China BioPharma ETF buyer in Q3 2023 was Jane Street, an estimated $113K added.

Based on aggregated 13F filings for Q3 2023.